Latest news with #VidhiShanghvi
India.com
20-06-2025
- Business
- India.com
Meet woman, daughter of India's richest pharma tycoon, she now leads Rs 3950000000000 company, she is…, her business is…
Vidhi Shanghvi, Sun Pharma Vidhi Shanghvi is daughter of Dilip Shanghvi, a famous Pharma businessman. She is in headlines for her role in Sun Pharma, one of India's biggest pharmaceutical companies. His net worth is around $25 billion and known as India's richest pharma billionaire. He is also among the top 100 richest people in the world. But now, his daughter Vidhi Shanghvi has also started handling his business. Who Is Vidhi Shanghvi? Vidhi Shanghvi is an Executive Director in Sun Pharma. After 13 years of experience, she now leads Sun Pharma's Consumer Healthcare and India Distribution. Sun Pharma was founded by her father, Dilip Shanghvi in 1983. They started making psychiatric drugs and slowly became India's most valuable pharma company, with a market capitalisation of Rs 3.95 lakh crore. Vidhi was recently appointed as Whole-time Director for a five-year term. Vidhi Shanghvi Educational Background Vidhi graduated from the Wharton School at the University of Pennsylvania. In Sun Pharma, she used her education in marketing and consumer healthcare. She began her career at Sun Pharma in 2012 as a Brand Manager in the India Business division. Over the years, she has held several leadership positions. In 2014, she became the Marketing Head for one of the company's Cardiovascular Business Units. She also handled many marketing campaigns. After the merger of Ranbaxy with Sun Pharma, Vidhi Shanghvi became the Business Head of the company's Consumer Healthcare Division. She has played a big role in the growth of the products like Revital H and Volini in retail stores, pharmacies, and online platforms in India. She also has expertise in various fields like marketing, brand building, project and alliance management, and distribution. She is the founder of Mann Talks, a not-for-profit mental health initiative. This platform gives free, holistic mental health solutions to individuals for their mental well-being.
Time of India
18-06-2025
- Business
- Time of India
Meet Vidhi Shanghvi, daughter of India's richest pharma tycoon, steering a Rs 3.95 lakh crore company
Vidhi Shanghvi, daughter of India's pharma tycoon Dilip Shanghvi, is making headlines for her impressive role in Sun Pharma, one of India's biggest pharmaceutical companies. With a net worth of $25 billion, Dilip Shanghvi is India's richest pharma billionaire and among the top 100 richest people in the world. But now, all eyes are on his daughter Vidhi Shanghvi, who is slowly stepping into the limelight with her strong leadership and modern approach to business. Who is Vidhi Shanghvi? Vidhi Shanghvi is currently the Executive Director at Sun Pharma, a company founded by her father, Dilip Shanghvi in 1983. Sun Pharma started as a maker of psychiatric drugs and has grown to become India's most valuable pharma company, with a market capitalisation of ₹3.95 lakh crore. Vidhi was recently appointed as Whole-time Director for a five-year term, showing her growing influence within the company. Educational Background of Vidhi Shanghvi Following the footsteps of many billionaire heirs, Vidhi Shanghvi studied abroad to gain global exposure. She graduated from the prestigious Wharton School at the University of Pennsylvania, a top business school in the world. Her academic background has helped her bring fresh and innovative ideas to Sun Pharma, especially in areas like marketing and consumer healthcare. Career Journey at Sun Pharma Vidhi Shanghvi began her career at Sun Pharma in 2012 as a Brand Manager in the India Business division. Over the years, she has held several leadership positions. In 2014, she became the Marketing Head for one of the company's Cardiovascular Business Units. She led many successful marketing campaigns and was instrumental in improving business operations and initiating digital transformation projects. Leading Sun Pharma's Consumer Healthcare and Distribution In 2015, after the merger of Ranbaxy with Sun Pharma, Vidhi Shanghvi was made the Business Head of the company's Consumer Healthcare Division. Under her leadership, this division has grown rapidly. She has played a key role in boosting the presence of popular products like Revital H and Volini across retail stores, pharmacies, and online platforms in India. Apart from Consumer Healthcare, Vidhi Shanghvi also leads India Distribution – a crucial part of Sun Pharma's value chain. Her efforts have helped improve supply efficiency and expand reach across the country. Over 13 Years of Experience in Pharma Sector With more than 13 years of professional experience, Vidhi Shanghvi has built expertise in various fields, including marketing, brand building, project and alliance management, and distribution. Her dynamic leadership style and strategic thinking have earned her recognition within the industry. Vidhi Shanghvi's Passion for Mental Health Beyond her corporate role at Sun Pharma, Vidhi Shanghvi is also deeply committed to mental health. She is the founder of Mann Talks, a not-for-profit mental health initiative. This platform provides free, holistic mental health solutions and encourages individuals to take charge of their mental well-being. What is Dilip Shanghvi's Net Worth? Dilip Shanghvi, founder of Sun Pharma, has an estimated net worth of $25.8 billion, according to Forbes. As of today, June 18, he is the 77th richest person in the world and remains one of the most successful entrepreneurs in India. His vision and leadership have shaped Sun Pharma into a global pharmaceutical giant. Vidhi Shanghvi's Brother Also Plays a Key Role Vidhi Shanghvi's brother, Aalok Shanghvi, is also part of the leadership at Sun Pharma. A few months ago, he was promoted to the position of Chief Operating Officer (COO), making it a truly family-led business. Vidhi Shanghvi is clearly following in the footsteps of her father Dilip Shanghvi, but she is also building her own legacy at Sun Pharma. With a strong academic background, diverse industry experience, and a clear passion for healthcare and innovation, Vidhi Shanghvi is emerging as a powerful new-age leader in the Indian pharmaceutical sector.
Time of India
18-06-2025
- Business
- Time of India
Meet Vidhi Shanghvi, daughter of India's richest pharma billionaire
Vidhi Shanghvi, daughter of India's pharma tycoon Dilip Shanghvi, is making headlines for her impressive role in Sun Pharma, one of India's biggest pharmaceutical companies. With a net worth of $25 billion, Dilip Shanghvi is India's richest pharma billionaire and among the top 100 richest people in the world. But now, all eyes are on his daughter Vidhi Shanghvi, who is slowly stepping into the limelight with her strong leadership and modern approach to business. Who is Vidhi Shanghvi? Vidhi Shanghvi is currently the Executive Director at Sun Pharma, a company founded by her father, Dilip Shanghvi in 1983. Sun Pharma started as a maker of psychiatric drugs and has grown to become India's most valuable pharma company, with a market capitalisation of ₹3.95 lakh crore. Vidhi was recently appointed as Whole-time Director for a five-year term, showing her growing influence within the company. Educational Background of Vidhi Shanghvi Following the footsteps of many billionaire heirs, Vidhi Shanghvi studied abroad to gain global exposure. She graduated from the prestigious Wharton School at the University of Pennsylvania, a top business school in the world. Her academic background has helped her bring fresh and innovative ideas to Sun Pharma, especially in areas like marketing and consumer healthcare. Career Journey at Sun Pharma Vidhi Shanghvi began her career at Sun Pharma in 2012 as a Brand Manager in the India Business division. Over the years, she has held several leadership positions. In 2014, she became the Marketing Head for one of the company's Cardiovascular Business Units. She led many successful marketing campaigns and was instrumental in improving business operations and initiating digital transformation projects. Leading Sun Pharma's Consumer Healthcare and Distribution In 2015, after the merger of Ranbaxy with Sun Pharma, Vidhi Shanghvi was made the Business Head of the company's Consumer Healthcare Division. Under her leadership, this division has grown rapidly. She has played a key role in boosting the presence of popular products like Revital H and Volini across retail stores, pharmacies, and online platforms in India. Apart from Consumer Healthcare, Vidhi Shanghvi also leads India Distribution – a crucial part of Sun Pharma's value chain. Her efforts have helped improve supply efficiency and expand reach across the country. Over 13 Years of Experience in Pharma Sector With more than 13 years of professional experience, Vidhi Shanghvi has built expertise in various fields, including marketing, brand building, project and alliance management, and distribution. Her dynamic leadership style and strategic thinking have earned her recognition within the industry. Vidhi Shanghvi's Passion for Mental Health Beyond her corporate role at Sun Pharma, Vidhi Shanghvi is also deeply committed to mental health. She is the founder of Mann Talks, a not-for-profit mental health initiative. This platform provides free, holistic mental health solutions and encourages individuals to take charge of their mental well-being. What is Dilip Shanghvi's Net Worth? Dilip Shanghvi, founder of Sun Pharma, has an estimated net worth of $25.8 billion, according to Forbes. As of today, June 18, he is the 77th richest person in the world and remains one of the most successful entrepreneurs in India. His vision and leadership have shaped Sun Pharma into a global pharmaceutical giant. Vidhi Shanghvi's Brother Also Plays a Key Role Vidhi Shanghvi's brother, Aalok Shanghvi, is also part of the leadership at Sun Pharma. A few months ago, he was promoted to the position of Chief Operating Officer (COO), making it a truly family-led business. Vidhi Shanghvi is clearly following in the footsteps of her father Dilip Shanghvi, but she is also building her own legacy at Sun Pharma. With a strong academic background, diverse industry experience, and a clear passion for healthcare and innovation, Vidhi Shanghvi is emerging as a powerful new-age leader in the Indian pharmaceutical sector. For the latest and more interesting financial news, keep reading Indiatimes Worth. Click here
India.com
03-06-2025
- Business
- India.com
Meet woman, an Indian, heir to Rs 4000000000000 business, she is…, her business is…
Vidhi Shanghvi, Sun Pharma Vidhi Shanghvi is the daughter of Dilip Shanghvi. She plays an important role in Sun Pharmaceutical Industries along with brother Aalok Shanghvi. The healthcare business is of Rs 4.35 lakh crore. She did bachelor's in Economics from the Wharton School of the University of Pennsylvania. As per Forbes, Dilip Shanghvi is India's richest healthcare billionaire, with a net worth of around $29.2 billion as of December 15, 2024. Connection To Mukesh Ambani Vidhi is married to Vivek Salgaocar who is son of Goan industrialists Shiv and Ranjana Salgaocar. The Salgaoncars are connected to the Ambanis according to the Economic Times report. One of Mukesh and Anil Ambanis' sisters, Deepti, is married to Dattaraj Salgaocar, brother of Shiv Salgaoncar. Vidhi is the Vice President and Head of Consumer Healthcare, Nutrition, and India Distribution in Sun Pharma. She also developed Sun Pharma like an MNC for more than 10 years. The report also said that Vidhi is a non-executive director at Sun Pharma Advanced Research Company, SPARC is Sun Pharma's subsidiary deals in clinical-stage biopharmaceutical products. Vidhi works for mental health related issues and has founded a non-profit organisation which helps the people to work on their mental health and provide solutions. Sun Pharma Industries According to the official website, Sun Pharmaceutical Industries is the fourth largest specialty generic pharmaceutical company in the world. It earns global revenues of $ 5.4 billion. It has 43 manufacturing facilities, and provides 'high-quality, affordable medicines, trusted by healthcare professionals and patients', to more than 100 countries across the globe.
Mint
01-06-2025
- Business
- Mint
Indian pharma's young blood takes over as drug dynasties crack the succession code
Some of India's largest pharmaceutical firms, including Sun Pharmaceutical Industries Ltd and Torrent Pharmaceuticals Ltd, are priming the next generation of their promoter families to take over the reins. On 20 May, Torrent Pharma announced the appointment of Aman Mehta (33), son of chairman Samir Mehta and a third-generation member of the Torrent Group's founder family, as managing director effective 1 August. The company said in a press statement that the appointment was part of 'our long-term strategic vision and succession planning". The same week, Sun Pharma announced the appointment of Vidhi Shanghvi, daughter of founder and managing director Dilip Shanghvi, as a whole time director. A few months ago, Sun Pharma elevated Aalok Shanghvi (40), Dilip Shanghvi's son, as chief operating officer. Other pharma companies like Lupin Ltd too have seen the next generation of their promoter families take charge in recent years. With the Indian pharmaceutical industry growing at a significant rate, the top companies in the sector are being closely watched for the evolution they are undertaking. Experts believe such successions must be planned with foresight, factoring in ideal transition times, grooming, and the role of other veteran executives in shaping up the incoming leaders. 'If one has to think about a template, I think a good template is one where there is a fair bit of overlap between the senior generation and the next generation. And the next generation gets a good chance to actually experience different parts of the business," said Amit Misra, managing director with consultancy firm Alvarez and Marsal's healthcare and life sciences practice in Mumbai. Aman Mehta, the newly appointed managing director of Torrent Pharma, is a whole-time director at Torrent Pharma. He was appointed as a director in 2022 and has been primarily involved with Torrent Pharma's India business, the company's largest revenue contributor. According to Torrent's press statement, Mehta played an instrumental role in the integration of the Unichem Laboratories Ltd acquisition and the strategic identification and integration of Curatio Healthcare Pvt. Ltd. Torrent's acquisition of Unichem's branded India and Nepal business in 2017 significantly boosted its presence in key segments. Torrent acquired 100% of Curatio in 2022. Similarly, Aalok Shanghvi, who was brought into the Sun Pharma fold in 2006, has handled various roles in marketing, research and development, project management, purchase, and communications, according to information on the company's website. Over the past two decades, Shanghvi has headed Sun's business in Bangladesh and later emerging markets, spanning 80 countries. Subsequently, he also took charge of Sun's global generic R&D, global generic business development, and API (active pharmaceutical ingredients) functions. Vidhi Shanghvi began her career at Sun Pharma in 2012 as a brand manager within the India business, and took over as business head of Sun Pharma's consumer healthcare business in 2015, following its merger with Ranbaxy Laboratories Ltd. 'Promoters need to not parachute their progeny into the boards, but groom them from the shop floor, be it in an accelerated manner, and then expose them to internal and external stakeholders," said Shriram Subramanian, founder and managing director of InGovern Research Services. The role of incumbent senior executives and how they evolve must also be planned, he said. 'At least the senior level executives' succession planning should be a process and discussed at the board level," Subramanian said, adding that uncertainties around leadership must be factored in and planned for. An ideal transition would involve a transition of erstwhile leadership as well, said Misra of Alvarez and Marsal. 'In the sense that when you are bringing in the next generation side by side, you also start to help them choose their team, while some of the stalwarts remain in advisory positions," he explained. Also read | Mint Explainer: What sparks family feuds in Indian corporations? Corporate successions: A tricky path India's corporate landscape is riddled with high-profile family disputes even in instances where the promoter families had drawn up legal frameworks to ensure a smooth transition. Factions of the Kirloskar family are feuding over a 2009 deed of family settlement that outlined the distribution of ownership, management, and control of various Kirloskar entities—including Kirloskar Brothers Ltd and Kirloskar Oil Engines Ltd—among different branches of the family. Babasaheb Kalyani, the billionaire promoter of the Kalyani group, and his sister Sugandha Hiremath have been in a dispute for longer than a decade over the family's group companies such as Bharat Forge Ltd and Kalyani Steels Ltd, as well as private assets like land, real estate, and jewellery. The Lodha brothers—real estate developers Abhishek and Abhinandan—only last month resolved their dispute over the 'Lodha' brand identity after a longdrawn mediation and with the guidance of their parents. Messy legal disputes aside, corporate successions tend to be mired in other seemingly mundane challenges that need to be factored in. For instance, corporate successors following in the footsteps of senior family members who built successful businesses would want to develop their own styles and strategies while continuing the company's growth and legacy. 'The challenge for the next generation is to retain the differentiating factor or the competitive edge as far as the company is concerned," Misra said. 'If a successor tries to just cut copy-paste, it won't work because that did not work even in the case of the previous generation," he added. Also read | Why do business families delay the inevitable: Succession planning? For companies facing a vacuum when it comes to finding successors from within the family, the focus needs to be on bringing in professional talent who align with the firm's culture and vision, while also fostering loyalty and longevity in this leadership. Take the case of Cipla. After heir apparent Kamil Hamied, nephew of Cipla doyen Dr. Y.K. Hamied, stepped down as chief strategy officer in 2015 to pursue personal interests, the company brought in Umang Vohra, former head of Dr. Reddy's Laboratories Ltd's North America business, as its global chief financial officer. In 2016, Cipla appointed him global CEO and managing director. What is important for the continuity of a successful business is empowering the successors—be it family members or a professional team—and ensuring they understand the company's needs, experts said. 'The point remains that even in cases where the vacuum is not there, empowering some of these people so that their leadership styles start getting noticed and they get the opportunity to be known, is extremely important," Misra emphasised.
